argentina
Cohortias – New regulation make Argentina an excellent choice for clinical research.
The new regulation will accelerate the evaluation process from 160 business days to 70 days or less.
Bio international
Cohortias – The BIO International Convention 2022.
For the first time in three years, the BIO International Convention will be back fully in person in San Diego, California.
type 2
Clinical Trial – Phase 1 of oral type 2 diabetes new therapy.
In the trial, GLY-200 was found to be well-tolerated across all tested dose levels without any safety signals detected.
PTCL
First-in-Human – Phase 1/2 refractory PTCL therapy.
A Phase II trial will begin to support registration, once Myeloid establishes the recommended dose.
booster
Clinical Trial – Phase 2 new covid-19 booster trial.
In the trial, vaccination with ABNCoV2 led to a substantial improvement in neutralizing antibodies against the Omicron variant.
osteoarthritis
First-in-Human – Phase 3 knee osteoarthritis trial.
The trial will evaluate the change in pain and function following subcutaneous injections of PPS versus placebo.
hepatocellular
Clinical Trial – Phase 2 hepatocellular carcinoma therapy.
The open-label trial will assess the safety and efficacy of GT90001 plus Nivolumab in patients with advanced HCC.
glioblastoma multiforme
Clinical Trial – Treatment for glioblastoma multiforme.
Assessing the overall survival is the primary endpoint of the global trial.
osteoporosis
First-in-Human – Phase 1 osteoporosis drug trial.
The trial will assess the safety, tolerability, and pharmacokinetics of TST002 to treat individuals with osteoporosis.
hypersomnia
Clinical Trial – Phase 3 idiopathic hypersomnia treatment.
The randomized, double-blind trial of Wakix will enroll nearly 200 IH patients in 60 to 80 trial sites in the US.